Company news
Double Bond Pharmaceutical International Ab Class B (NGM:DBP.B) news
Double Bond Pharmaceutical International Ab Class B news releases on 6ix. Latest, May 22, 2026: DBP.B: Q1 2026 delivered narrowed losses and major clinical…
Press releases & updates
DBP.B: Q1 2026 delivered narrowed losses and major clinical validation for Temodex
May 22, 2026
DBP.B: Equity restored and net loss reduced as SI-053 development progressed, but funding needs persist
February 26, 2026
DBP.B: Improved results and restored equity as S1053 advances toward potential partnerships
November 13, 2025
DBP.B: Revenue and net loss improved, with strong project progress and a major rights issue launched
August 25, 2025
DBP.B: Revenues rose and losses narrowed as SI053 clinical trial preparations were completed
May 22, 2025
DBP.B: Losses narrowed as SI-053 advanced; funding secured, liquidity sufficient into Q3 2025
February 26, 2025
DBP.B: SI-053 clinical trial preparations advanced, with improved results and new financing secured
November 14, 2024
DBP.B: SI-053 clinical progress and new partnerships drive Double Bond Pharmaceutical's strategic focus
August 26, 2024